Drugs / Oktokog alpha
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03915080 | Dec 2016 → Apr 2021 | hemophilia A | Lund University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oktokog alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03915080 ↗ |
| Known as | Advate | “Oktokog alpha (Advate)” NCT03915080 ↗ |
| Route | Intravenous | “using intravenous injection of oktokog alpha” NCT03915080 ↗ |